about
Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patientsAllopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials.Sex differences in the limit to deficit accumulation in late middle-aged and older Chinese people: results from the Beijing Longitudinal Study of Aging.Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study.Global metabolomic profiling of acute myocarditis caused by Trypanosoma cruzi infectionUric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review.Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.Xanthine oxidase and uric Acid in atrial fibrillation.Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study.Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.Xanthine oxido-reductase, free radicals and cardiovascular disease. A critical review.Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy.Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.Impact of allopurinol on risk of myocardial infarction.Drug Therapy for Stable Angina Pectoris.Management of stable angina: A commentary on the European Society of Cardiology guidelines.Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis.Pharmacological effects of Chatuphalatika in hyperuricemia of gout.Mechanism-based pharmacokinetic-pharmacodynamic modeling of salvianolic acid A effects on plasma xanthine oxidase activity and uric acid levels in acute myocardial infarction rats.A new sensitive and quantitative chemiluminescent assay to monitor intracellular xanthine oxidase activity for rapid screening of inhibitors in living endothelial cells.Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease
P2860
Q30002373-CE1233AD-A384-4446-B789-7F272F704352Q30248398-FACF2A23-C849-48A5-961C-83B2DAAD4140Q33616007-5125B622-F401-4C27-941E-6D4CE65B192EQ33887961-27662C35-A1E7-4B7D-89F1-592FEFFB0028Q34549735-968C0DBB-1D54-4C37-9915-A40F88A99955Q34682703-B50AE84A-E20A-4F38-8573-ECB144B95AEAQ35642254-2DB28C26-EEF7-427E-80DA-C083901D2689Q35985640-34561BE6-ECE5-46A2-BEF6-5AFD881AEBA9Q36233048-2471181D-498B-4365-8251-B41715C32E4CQ36306524-27661AC3-EBE6-4C31-A261-B0828FF5D803Q38152735-21F25690-473B-4BCC-B7A2-F71E607E590FQ38428834-52218EDC-A3CF-4758-ABC0-2A4C8DD80950Q38853112-ED456C27-4AFA-4393-8290-63618DC76807Q39033643-89593921-CF16-4628-8B58-376A22737288Q39102158-37C46FBF-7473-45B0-986E-D98A050ABFD8Q39738089-196ABD53-FD6B-4B70-9EBF-A3B97A2302FEQ40742040-4FCE0635-383F-47B9-BFA0-D6206784E35FQ48315367-16FD771B-A5FC-4A30-9074-C4D8DF144C68Q50648955-47F1427A-A790-4611-A526-010095C48AFBQ53064592-5A84FB76-EC8B-4672-B93F-902BF5033E98Q58129718-10C854D0-A820-489B-8F81-404613EB574D
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Allopurinol as a cardiovascular drug.
@en
Allopurinol as a cardiovascular drug.
@nl
type
label
Allopurinol as a cardiovascular drug.
@en
Allopurinol as a cardiovascular drug.
@nl
prefLabel
Allopurinol as a cardiovascular drug.
@en
Allopurinol as a cardiovascular drug.
@nl
P2093
P1433
P1476
Allopurinol as a cardiovascular drug.
@en
P2093
Anita Kelkar
William H Frishman
P304
P356
10.1097/CRD.0B013E318229A908
P577
2011-11-01T00:00:00Z